Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus chemotherapy as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2500108027Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Hospital of Lanzhou University. Primary endpoint: Pathological Complete Response (pCR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500108027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108027.